Peter Schmid, MD, PhD, on Triple-Negative Breast Cancer: Updated Results on Pembrolizumab Plus Chemotherapy

November 07, 2023 By The ASCO Post Staff

Peter Schmid, MD, PhD, of Queen Mary University of London, discusses phase III findings from the KEYNOTE-522 study, which showed neoadjuvant pembrolizumab plus chemotherapy followed by adjuvant pembrolizumab continues to improve event-free survival compared with neoadjuvant chemotherapy alone in patients with early-stage triple-negative breast cancer, regardless of pathologic complete response (Abstract LBA18).

Related Content